Exact Sciences Corporation (NASDAQ:EXAS) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, October 24th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.
Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The business had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. On average, analysts expect Exact Sciences Corporation to post $-1.19 EPS for the current fiscal year and $-0.8 EPS for the next fiscal year.
Exact Sciences Corporation (NASDAQ EXAS) opened at 49.15 on Friday. Exact Sciences Corporation has a 52 week low of $13.05 and a 52 week high of $50.65. The stock’s 50 day moving average is $45.56 and its 200-day moving average is $36.98. The firm’s market capitalization is $5.85 billion.
ILLEGAL ACTIVITY WARNING: “Exact Sciences Corporation (EXAS) Scheduled to Post Quarterly Earnings on Tuesday” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://stocknewstimes.com/2017/10/22/exact-sciences-corporation-exas-scheduled-to-post-quarterly-earnings-on-tuesday.html.
In other news, SVP D Scott Coward sold 29,115 shares of Exact Sciences Corporation stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $47.16, for a total value of $1,373,063.40. Following the transaction, the senior vice president now owns 64,991 shares of the company’s stock, valued at approximately $3,064,975.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jeffrey Thomas Elliott sold 5,846 shares of Exact Sciences Corporation stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $39.41, for a total transaction of $230,390.86. Following the completion of the transaction, the chief financial officer now directly owns 19,861 shares in the company, valued at approximately $782,722.01. The disclosure for this sale can be found here. Insiders sold a total of 237,444 shares of company stock worth $10,412,421 in the last ninety days. Corporate insiders own 4.00% of the company’s stock.
Several analysts recently weighed in on EXAS shares. Vetr downgraded shares of Exact Sciences Corporation from a “hold” rating to a “sell” rating and set a $34.70 price objective on the stock. in a research report on Wednesday, July 12th. Leerink Swann set a $45.00 price objective on shares of Exact Sciences Corporation and gave the company a “buy” rating in a research report on Thursday, August 24th. Roth Capital lifted their price objective on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, July 26th. Craig Hallum lifted their price objective on shares of Exact Sciences Corporation from $35.00 to $41.00 in a research report on Friday, July 7th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $42.00 price objective (up from $38.00) on shares of Exact Sciences Corporation in a research report on Thursday, July 20th. Five analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $44.91.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.